Abstract:Background: Cognitive impairment associated with schizophrenia (CIAS) represents a distinct, persistent, and core group of schizophrenia symptoms. Cognitive symptoms have been shown to have an impact on quality of life. There are several published CIAS measures, but none based on direct patient self-report. It is important to capture the patient's perspective to supplement performancebased outcome measures of cognition to provide a complete picture of the patient's experience. This paper describes additional validation work on the Patient-Reported Experience of Cognitive Impairment in Schizophrenia (PRECIS) instrument. Methods: Data from two large, international, pharmaceutical clinical trials in medically and psychiatrically stable English-speaking patients with schizophrenia and 88 healthy controls were analyzed. An exploratory factor analysis (EFA) was conducted in one trial (n = 215), using the original 35-item PRECIS. The factor structure suggested by EFA was further evaluated using item response theory (IRT; Samejima's graded response model), and tested using confirmatory factor analysis (CFA). Both EFA and CFA results were tested in a second trial with similar inclusion/exclusion characteristics (n = 410). Additional statistical properties were evaluated in healthy controls. Results: EFA suggested that the best solution after item reduction suggested a factor structure of 6 factors based on 26 items (memory, communication, self-control, executive function, attention, sharpness of thought), supporting a total score, with an additional 2-item bother score (28 items in all). IRT analysis indicated the items were well-ordered within each domain. The CFA demonstrated excellent model fit, accounting for 69% of the variance. The statistical properties of the 28-item version of the PRECIS were confirmed in the second trial. Evidence for internal consistency and test-retest reliability was robust. Known-groups validity was supported by comparison of healthy controls with patients with schizophrenia. Correlations indicated moderate associations between PRECIS and functioning instruments like the Schizophrenia Cognition Rating Scale (SCoRS), but weak correlations with performance-based outcomes like MATRICS Consensus Cognitive Battery (MCCB). Discussion: Using two clinical trial samples, we identified a robust factor structure for the PRECIS and were able to replicate it in the second sample. Evaluation of the meaningful score difference (MSD) should be repeated in future studies, as these samples did not show enough change for it to be evaluated. Conclusions: This analysis provides strong evidence for the reliability and validity of the PRECIS, a 28-item, patient-reported instrument to assess cognitive impairment associated with schizophrenia. The correlation with functioning and the weak correlation with performance on cognitive tasks suggests that patient reports of cognitive impairment measure a unique aspect of patient experience.

The screen for cognitive impairment in psychiatry (SCIP) is associated with disease severity and cognitive complaints in major depression

Validation of the Six-Item Screener to Screen for Cognitive Impairment in Primary Care Settings in China

Effects of Combining Pharmacotherapy with Cognitive Remediation

Screen for Cognitive Impairment in Psychiatry (SCIP): Adaptation and validation for Portuguese Version

The Discriminant Validity of Single-Question Assessments of Subjective Cognitive Complaints in an Asian Older Adult Population.

Validation of the short-cognitive inventory of subjective distress (S-CISD)

A Preliminary Study of the Six-Item Screener in Detecting Cognitive Impairment

The McCusker Subjective Cognitive Impairment Inventory (McSCI): a novel measure of perceived cognitive decline

Six-Item Screener to Identify Cognitive Impairment Among Potential Subjects for Clinical Research

Adaptation and Validation of the Psychological Consequences of Screening Questionnaire (PCQ) for Cognitive Screening in Primary Care

Psychometric evaluation of the patient-reported experience of cognitive impairment in schizophrenia (PRECIS) scale

Is the geriatric depression scale a reliable screening tool for depressive symptoms in elderly patients with cognitive impairment?

Validation study of "Santé-Cerveau", a digital tool for early cognitive changes identification

Clinical evaluation of brief cognitive assessment measures for patients with severe dementia

P50 sensory gating, cognitive deficits and depressive symptoms in first-episode antipsychotics-naïve schizophrenia

Association between Subjective Cognitive Complaints and Incident Functional Impairment in Parkinson's Disease

Diagnostic Accuracy of Cognitive Screening Tools under Different Neuropsychological Definitions for Poststroke Cognitive Impairment.

Validity of the Tablet-Based Digital Cognitive Test (SCST) in Identifying Different Degrees of Cognitive Impairment

Delirium Screening in Neurocritical Care and Stroke Unit Patients: A Pilot Study on the Influence of Neurological Deficits on CAM-ICU and ICDSC Outcome

P152: Early detection and evolution of Mild Behavioral Impairment in a sample of people with subjective cognitive complaints

P198: Correlation between depressive symptom severity and functional status in patients with mild cognitive impairment.